← Back to Clinical Trials
Recruiting NCT06011525

NCT06011525 Prevention of Alopecia in Patients With Localised Breast Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06011525
Status Recruiting
Phase
Sponsor Centre Francois Baclesse
Condition Chemotherapy-induced Alopecia
Study Type INTERVENTIONAL
Enrollment 196 participants
Start Date 2023-08-03
Primary Completion 2026-09-03

Trial Parameters

Condition Chemotherapy-induced Alopecia
Sponsor Centre Francois Baclesse
Study Type INTERVENTIONAL
Phase N/A
Enrollment 196
Sex FEMALE
Min Age 18 Months
Max Age N/A
Start Date 2023-08-03
Completion 2026-09-03
Interventions
standard cold capscalp-cooling technique

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The prevention of chemotherapy-induced alopecia (CIA) is still imperfectly managed in France. Strengthening the evidence base on the benefits of strategies to prevent CIA, based on robust methodologies, remains a prerequisite for better integration of appropriate supportive care for patients receiving chemotherapy. This research should provide new knowledge on the benefits of scalp refrigeration during anthracycline- and taxane-based chemotherapy in preventing ACI, for each of the 2 refrigeration techniques. In addition to effectiveness in preventing ACI, quality of life, self-image and satisfaction with care will be assessed by patients during and after chemotherapy. The medico-economic aspects will also be assessed for each of the two refrigeration modalities. The results of the various proposed assessments will be used to guide the choice between these two techniques for preventing ACI.

Eligibility Criteria

Inclusion Criteria: * Age \>18 * Female * Histologically proven diagnosis of localised, non-metastatic breast cancer * Indication for neo-adjuvant or adjuvant anthracycline and taxane chemotherapy (3 or 4 EC100 followed by 3 Docetaxel or 3 or 4 EC100 plus 9 to 12 Paclitaxel); HER-positive status is not a non-inclusion criterion. * Patient willing to be photographed to assess IFA * Fluency in French * Patient affiliated to a social security scheme * Signature of informed consent Exclusion Criteria: * History of neck pain * Pre-existing alopecia * Participation in another trial * Dermatosis of the scalp * Contraindication to scalp cooling * History of migraines, stroke or hyperthyroidism * History of scalp metastases * Sensitivity to cold, cold agglutinin disease, cryoglobulinaemia, cryofibrinogenaemia or post-traumatic cold dystrophy. * Malignant haemopathies * History of chemotherapy treatment * Indication for cerebral irradiation * Pregnant or breast-feeding patient * Raynaud's syndro

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology